Structum therapy of patients with rheumatoid arthri-tis

Aim. To study efficacy of the chondroprotector chondroitin sulphate (structum, Pier Fabr Medicament Production, France) in patients with rheumatoid arthritis (RA) and secondary osteoarthrosis of the knee joints. Material and methods. 15 women with a long history of RA (mean duration 11.9 years) ente...

Full description

Bibliographic Details
Main Authors: Ye I Shmidt, I V Belozerova, F M Akhmedzhanov, D G Soldatov
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2004-11-01
Series:Терапевтический архив
Subjects:
Online Access:https://ter-arkhiv.ru/0040-3660/article/view/29972
_version_ 1818555175483211776
author Ye I Shmidt
I V Belozerova
F M Akhmedzhanov
D G Soldatov
author_facet Ye I Shmidt
I V Belozerova
F M Akhmedzhanov
D G Soldatov
author_sort Ye I Shmidt
collection DOAJ
description Aim. To study efficacy of the chondroprotector chondroitin sulphate (structum, Pier Fabr Medicament Production, France) in patients with rheumatoid arthritis (RA) and secondary osteoarthrosis of the knee joints. Material and methods. 15 women with a long history of RA (mean duration 11.9 years) entered an open non-randomized trial of structum. The patients had a severe progressive highly active RA with a definite x-ray stage of the disease. 13 patients had a positive rheumatoid factor (1:80 to 1:1280) and involved knee joints which had been affected for 1 to 10 years (mean 5.3 years). The second x-ray stage was in 8 patients, the third stage of knee joints arthrosis was in 7 ones. A marked pain syndrome in the knee joints upon movement (mean 64.7 mm by VAS) was observed in all the examinees and at rest (mean 28 mm by VAS) in 13 of 15 patients. Structum was given according to a standard scheme: 500 mg 3 times a day for 3 weeks than 500 mg 2 times a day for up to 6 months. Basic drugs for RA were the same for all the observation period. Results. Structum noticeably improved knee joint function (mean Leken's index 12.8, 11.3 and 9.4 scores before the treatment, on treatment month 3 and 6. Movement pain syndrome VAS reduced from 64.7 mm at the strart to 51 mm 3 months and 37.5 mm 6 months later, rest VAS - from 19 to 10.3 and 6.4 mm, respectively. The demand in intraarticular glucocorticoids went down from 52 injections at the start of therapy to 6 after 6 months. Side effects for 6 months were absent. Overall efficacy was good (73.3% and 80%) as judged by the doctors and patients, respectively. After 6 months of therapy control x-rays found no progression of destructive changes in the knee joints (by MRI - in 4 patients). Conclusion. Structum has a marked positive therapeutic effect in patients with severe and long-term course of RA with associated pronounced secondary joint arthrosis.
first_indexed 2024-12-12T09:49:46Z
format Article
id doaj.art-26ed4dbfca94481db5436ad602b16e76
institution Directory Open Access Journal
issn 0040-3660
2309-5342
language Russian
last_indexed 2024-12-12T09:49:46Z
publishDate 2004-11-01
publisher "Consilium Medicum" Publishing house
record_format Article
series Терапевтический архив
spelling doaj.art-26ed4dbfca94481db5436ad602b16e762022-12-22T00:28:18Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422004-11-017911939527000Structum therapy of patients with rheumatoid arthri-tisYe I ShmidtI V BelozerovaF M AkhmedzhanovD G SoldatovAim. To study efficacy of the chondroprotector chondroitin sulphate (structum, Pier Fabr Medicament Production, France) in patients with rheumatoid arthritis (RA) and secondary osteoarthrosis of the knee joints. Material and methods. 15 women with a long history of RA (mean duration 11.9 years) entered an open non-randomized trial of structum. The patients had a severe progressive highly active RA with a definite x-ray stage of the disease. 13 patients had a positive rheumatoid factor (1:80 to 1:1280) and involved knee joints which had been affected for 1 to 10 years (mean 5.3 years). The second x-ray stage was in 8 patients, the third stage of knee joints arthrosis was in 7 ones. A marked pain syndrome in the knee joints upon movement (mean 64.7 mm by VAS) was observed in all the examinees and at rest (mean 28 mm by VAS) in 13 of 15 patients. Structum was given according to a standard scheme: 500 mg 3 times a day for 3 weeks than 500 mg 2 times a day for up to 6 months. Basic drugs for RA were the same for all the observation period. Results. Structum noticeably improved knee joint function (mean Leken's index 12.8, 11.3 and 9.4 scores before the treatment, on treatment month 3 and 6. Movement pain syndrome VAS reduced from 64.7 mm at the strart to 51 mm 3 months and 37.5 mm 6 months later, rest VAS - from 19 to 10.3 and 6.4 mm, respectively. The demand in intraarticular glucocorticoids went down from 52 injections at the start of therapy to 6 after 6 months. Side effects for 6 months were absent. Overall efficacy was good (73.3% and 80%) as judged by the doctors and patients, respectively. After 6 months of therapy control x-rays found no progression of destructive changes in the knee joints (by MRI - in 4 patients). Conclusion. Structum has a marked positive therapeutic effect in patients with severe and long-term course of RA with associated pronounced secondary joint arthrosis.https://ter-arkhiv.ru/0040-3660/article/view/29972rheumatoid arthritissecondary osteoarthrosistreatmentsulphatestructumchondroitin
spellingShingle Ye I Shmidt
I V Belozerova
F M Akhmedzhanov
D G Soldatov
Structum therapy of patients with rheumatoid arthri-tis
Терапевтический архив
rheumatoid arthritis
secondary osteoarthrosis
treatment
sulphate
structum
chondroitin
title Structum therapy of patients with rheumatoid arthri-tis
title_full Structum therapy of patients with rheumatoid arthri-tis
title_fullStr Structum therapy of patients with rheumatoid arthri-tis
title_full_unstemmed Structum therapy of patients with rheumatoid arthri-tis
title_short Structum therapy of patients with rheumatoid arthri-tis
title_sort structum therapy of patients with rheumatoid arthri tis
topic rheumatoid arthritis
secondary osteoarthrosis
treatment
sulphate
structum
chondroitin
url https://ter-arkhiv.ru/0040-3660/article/view/29972
work_keys_str_mv AT yeishmidt structumtherapyofpatientswithrheumatoidarthritis
AT ivbelozerova structumtherapyofpatientswithrheumatoidarthritis
AT fmakhmedzhanov structumtherapyofpatientswithrheumatoidarthritis
AT dgsoldatov structumtherapyofpatientswithrheumatoidarthritis